Ottawa, Oct. 29, 2022 (GLOBE NEWSWIRE) -- The global immune checkpoint inhibitors market size was accounted at USD 31.4 billion in 2021. The immune system's task is to safeguard the body's healthy cells from invasion by foreign substances (such as bacteria and cancer cells). Immunotherapy, which includes checkpoint inhibitors, is effective in treating cancers like lung and melanoma skin cancer. When immune cells with the name T cells have certain proteins on their surface, the immunological checkpoints are activated (recognizers). These checkpoints also interact with companion proteins in other cells, such as malignant cells. As a result, these cells assist in preventing the immune system from eliminating cancer.
Get the Free Sample Copy of Report@ https://www.precedenceresearch.com/sample/2281
Market Growth
Areas of cancer are treated with radiation and surgery, and the field of oncology is broad and includes a variety of application areas. Chemotherapy typically circulates via the bloodstream to treat patients' entire bodies, and doing so is referred to as systemic treatment. Treatment for cancer cells helps patients' immune systems fight cancer more successfully. The top cause of death in the world is cancer. Immune checkpoint inhibitors thereby prevent the growth of cancer cells and aid in their detection by the immune system or cells.
Immune cells that must be activated and deactivated in order to initiate an immune response and prevent the immune system from being harmed are targeted by immune checkpoint inhibitor medications. Additionally, a number of well-known companies are funding clinical development through R&D investments. The checkpoint inhibitor pembrolizumab was the first FDA-approved drug solely based on the presence of a genetic characteristic in a tumor, and it is used to treat MSI-H and dMMR cancers. Immune checkpoint inhibitors are a growing market due to ongoing rivalry in the industry.
Regional Analysis
The market was dominated by the North American area in 2021 as a result of the increasing number of oncology patients. The expansion of new drug development for cancer treatment is receiving more government money and support. Additionally, an increase in research and development for new and innovative pharmaceuticals on the market is aiding regional growth. The market for immune checkpoint inhibitors is expanding as a result of the government's support of new drug development for the treatment of cancer.
Report Insights:
- North America market has held 47% market share in 2021.
- By type, the PD-L1 inhibitor segment has held 64% market share in 2021 and is growing at a CAGR of 16.8%.
- By application, the lung cancer segment has accounted 37.5% market share in 2021.
- By region, Asia-Pacific region is poised to grow at a CAGR of 18.4% from 2022 to 2030.
Ask here for more customization study@ https://www.precedenceresearch.com/customization/2281
Scope of the Report
| Report Attributes | Details |
| Market Size in 2030 | USD 148.1 Billion |
| CAGR | 6.91% from 2022 to 2030 |
| Largest Market | North America |
| Fastest Growing Region | Asia Pacific |
| Base Year | 2021 |
| Forecast Year | 2022 to 2030 |
| Key Players | AstraZeneca PLC, Eli Lilly and Company (ARMO Biosciences.), Bristol-Myers Squibb Company, Roche Holding AG, Incyte Corporation, Novartis AG, GlaxoSmithKline PLC, F. Hoffmann-La Roche Ltd. (Genentech Inc.,), Sanofi, Merck & Co., Inc., Merck KGaA (EMD Serono Inc.), BeiGene Ltd, Shanghai Jhunsi Biosciences Ltd. |
Market Dynamics of Immune Checkpoint Inhibitors Market
Market Drivers
- Immune checkpoint inhibitors are a growing market due to ongoing rivalry in the industry. The market for immune checkpoint inhibitors is expanding due to factors such as the adoption of an unhealthy lifestyle, the rise in cancer cases, and genetic mutation and alteration that have an impact on the cost of healthcare in the nation.
- In addition, rising healthcare costs in this market, an increase in the use of immune checkpoint inhibitor medications in emerging regions, and technical advancements in cancer screening and broadcasting methods are all driving the immune checkpoint inhibitors industry's growth.
Market Restraints
- However, the high cost of product research and development subsequently raises the price of the finished product and related treatments, which is a factor that is anticipated to restrain the market growth for immune checkpoint inhibitors.
- Additionally, regulatory price limitation has resulted from the immune checkpoint medicines high price. It is also anticipated that the regulatory price cap on immune checkpoint inhibitors may impede the market's expansion.
- The immune checkpoint inhibitors market is also being constrained by advancing cancer therapeutic technology and growing public awareness of immune system disorders.
Market Opportunities
- In order to advance their research projects, worldwide players in the immune checkpoint inhibitors market frequently collaborate with businesses that combine their core capabilities. For instance, Merck, which is known as MSD outside of the United States and Canada, and Dynavax Technologies Corporation are investigating the potential synergistic effects of combining SD-101 from Dynavax with Keytruda and MK-1966, two immunological treatments from Merck.
- A rise in the need for cancer therapies, an expansion of R&D projects, and increased reimbursement practices provided by manufacturers and insurance firms in some nations are significant drivers of the global market's expansion.
Segmentation Insights
End-user Insight
Hospitals, specialized clinics, and academic & research institutions make up the three end-user segments of the global immune checkpoint inhibitors market. Due to its large customer base, rising healthcare costs, and rising cases of cancers like lung and bladder cancer, melanoma, Hodgkin lymphoma, and others, the hospitals & specialty clinics segment is anticipated to hold the largest market share in the global immune checkpoint inhibitors market over the forecast period.
Disease Indication Insight
Lung cancer accounted for a sizeable portion of illness indications overall. Advanced forms of lung cancer are targeted using immune checkpoint inhibitor medications. Immune checkpoint inhibitors approved by the FDA for the treatment of lung cancer, including ipilimumab, nivolumab, atezolizumab, and durvalumab, are what is fueling the market's expansion. Additionally, due to an increase in bladder cancer incidences, the bladder cancer sector is anticipated to grow at the quickest rate during the forecast period.
Related Reports
- Immunotherapy Drugs Market Research Report 2022 to 2030
- Monoclonal Antibodies Market Research Report 2022 to 2030
- In Vitro Diagnostics Market Research Report 2022 to 2030
Get Our Latest Press Releases@ https://www.precedenceresearch.com/press-releases
Recent Development
- Pembrolizumab (KEYTRUDA), which Merck received accelerated approval for from the USFDA in June 2019, will likely increase the company's market share during the forecast period is used to treat patients with metastatic SCLC who have progressed on or after platinum-based chemotherapy and at least one other prior line of therapy.
Market Segmentation
By Drug Type
- CTLA-4 Inhibitor
- PD-1 Inhibitor
- PD-L1 Inhibitor
By Disease Indication
- Lung Cancer
- Bladder Cancer
- Melanoma
- Hodgkin lymphoma
- Others
By End-Users
- Hospitals
- Specialty Clinics
- Academic & Research Institutions
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa (MEA)
Immediate Delivery Available | Buy this Premium Research Report@ https://www.precedenceresearch.com/checkout/2281
You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 9197 992 333
About Us
Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.
For Latest Update Follow Us:
https://www.linkedin.com/company/precedence-research/
https://www.facebook.com/precedenceresearch/
https://twitter.com/Precedence_R
